William D. Baird III Sells 40,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 40,000 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $570,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded up 1.45% during trading on Monday, hitting $14.74. 2,070,898 shares of the stock traded hands. The company’s market cap is $2.43 billion. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $16.60. The firm’s 50-day moving average price is $14.39 and its 200-day moving average price is $10.90.
Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The company had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.
A number of brokerages have commented on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.81.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA lifted its stake in Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 66,209 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Amicus Therapeutics by 5.7% during the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after purchasing an additional 41,711 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $1,057,000. Geode Capital Management LLC raised its position in shares of Amicus Therapeutics by 4.7% during the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock worth $8,323,000 after purchasing an additional 52,003 shares during the period. Finally, Morgan Stanley raised its position in shares of Amicus Therapeutics by 99.4% during the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after purchasing an additional 3,055,039 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.